Propanc Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Propanc Biopharma, Inc., a Delaware corporation with principal executive offices in Camberwell, Australia, filed this Current Report on Form 8-K on December 7, 2023, covering events occurring on December 4, 2023. The filing discloses the entry into a material definitive agreement involving the issuance of a convertible promissory note.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or existing debt levels. The primary financial metric disclosed is the issuance of a new debt instrument:
- Principal Amount: $45,000
- Purchase Price: $45,000
- Interest Rate: 8% per annum (increases to 22% upon default)
- Maturity Date: September 15, 2024
- Use of Proceeds: General working capital
Material Changes and Agreement Terms
The Company entered into a Securities Purchase Agreement with an investor to issue a convertible promissory note. Key terms include:
- Conversion Rights: The note is convertible into common stock at the investor's option after 180 days. The conversion price is set at 35% of the average of the lowest three traded prices during the ten trading days prior to conversion.
- Ownership Limitation: Conversions are subject to a 4.99% beneficial ownership limitation.
- Prepayment Terms: The Company may prepay the note during the first 180 days with a premium ranging from 110% to 129% of the face amount plus accrued interest, depending on the timing of prepayment. No prepayment right exists after the initial 180-day period.
- Reserve Requirement: The Company must maintain an initial reserve of at least 500% of the number of potential conversion shares.
Outlook, Risks, and Contingencies
The filing outlines several events of default that would render the note immediately due and payable, including:
- Failure to pay principal or interest when due.
- Failure to timely issue conversion shares.
- Failure to maintain the listing of common stock on at least one OTC market or equivalent exchange.
- Failure to comply with SEC reporting requirements.
- Insolvency, bankruptcy, or liquidation.
The note was issued pursuant to the private placement exemption under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D. The filing text does not provide specific management commentary on future operational outlook beyond the use of proceeds for working capital.
Investor Verification Checklist
- Verify the Company's current cash position and ability to service the 8% interest obligation or meet prepayment premiums.
- Confirm the Company's compliance with OTC market listing requirements to avoid an immediate event of default.
- Review the Company's authorized share count to ensure the 500% reserve requirement for conversion shares can be met without excessive dilution.
- Assess the impact of the 35% conversion discount on existing shareholders if the note is converted.
- Check for any subsequent filings regarding the Company's ability to maintain SEC reporting compliance.